We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| SpringWorks Therapeutics Inc | NASDAQ:SWTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 42.46 | 23.00 | 67.51 | 0 | 09:09:58 |
From Nov 2023 to May 2024
By Ben Glickman
SpringWorks Therapeutics has received approval from the Food and Drug Administration for its treatment of desmoid tumors.
The Stamford, Conn.-based biopharmaceutical company said that Ogsiveo had been approved for adults with progressing desmoid tumors who require systemic treatment.
Desmoid tumors are non-cancerous, soft-tissue tumors which can be life-threatening when they impact vital structures. SpringWorks said Ogsiveo was the first FDA-approved therapy for patients with desmoid tumors.
SpringWorks said the treatment would be available to order through certain specialty pharmacies and distributors in five to 10 business days.
The company plans to file a marketing authorization application for the treatment with European regulators in the first half of 2024.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 27, 2023 18:31 ET (23:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year SpringWorks Therapeutics Chart |
1 Month SpringWorks Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
